LY2835219 is primarily utilized in the field of oncology, specifically as a cyclin-dependent kinase (CDK) inhibitor. It targets CDK4 and CDK6, which play crucial roles in cell cycle regulation. By inhibiting these kinases, it helps to halt the proliferation of cancer cells, particularly in breast cancer and other solid tumors. This compound is often studied in clinical trials to evaluate its efficacy in combination with other therapies, such as hormone therapy, to enhance treatment outcomes. Its application is significant in addressing cancers that are resistant to conventional treatments, offering a potential pathway for improved patient prognosis.